# PBYI catalysts: PUMA BIOTECHNOLOGY, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pbyi/catalysts

> PUMA BIOTECHNOLOGY, INC. (PBYI) has 6 upcoming catalysts. The next is the alisertib topline data readout, Oct 2027 to Jan 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | PUMA BIOTECHNOLOGY, INC. |
| Ticker | PBYI (Nasdaq) |
| SEC CIK | 1401667 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pbyi |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 17, 2017 | [Nerlynx (neratinib maleate) FDA approval](https://sec-api.dev/pdufa/neratinib) | PBYI |  | completed, approved | "NDA208051 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170717, review_priority STANDARD; sponsor_name PUMA BIOTECH; product NERLYNX (NERATINIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208051%22)) |
| February 25, 2020 | [Nerlynx (neratinib maleate) label expansion decision](https://sec-api.dev/pdufa/neratinib) | PBYI |  | completed, approved | "NDA208051 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200225, review_priority STANDARD; sponsor_name PUMA BIOTECH; product NERLYNX (NERATINIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208051%22)) |
| July 29, 2020 | [Nerlynx (neratinib maleate) label expansion decision](https://sec-api.dev/pdufa/neratinib) | PBYI |  | completed, approved | "NDA208051 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200729, review_priority STANDARD; sponsor_name PUMA BIOTECH; product NERLYNX (NERATINIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208051%22)) |
| June 28, 2021 | [Nerlynx (neratinib maleate) label expansion decision](https://sec-api.dev/pdufa/neratinib) | PBYI |  | completed, approved | "NDA208051 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210628, review_priority STANDARD; sponsor_name PUMA BIOTECH; product NERLYNX (NERATINIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208051%22)) |
| Feb 2024 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with extensive-stage small cell lung cancer | completed | "In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| Nov 2024 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with HER2-negative, HR-positive metastatic breast cancer | completed | "In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| February 27, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "LOS ANGELES, Calif., Feb. 27, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/ex_783116.htm)) |
| May 8, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/ex_785138.htm)) |
| August 7, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm)) |
| Q4 2025 | [Alisertib interim data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer | scheduled | "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (Q4 2025) and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (Q4 2025)."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm)) |
| November 6, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm)) |
| 1H 2026 | [Alisertib interim data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer | scheduled | "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2026) and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (H1 2026)."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm)) |
| February 26, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/ex_916496.htm)) |
| May 7, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/ex_938051.htm)) |
| Q3 2026 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with extensive stage small cell lung cancer | scheduled | "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) initiation of enrollment in ALISCA®-Lung2, a Phase I/II trial of alisertib in combination with paclitaxel for the treatment of patients with extensive stage small cell lung cancer (Q3 2026)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm)) |
| August 6, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm)) |
| Sep 2026 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with advanced small cell lung cancer | completed | "In September 2026, Puma initiated ALISCA®-Lung2, a Phase II clinical trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| November 5, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| Oct 2027 to Jan 2028 | [Alisertib topline data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer | scheduled | "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06095505)) |
| October 2027 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer | scheduled | "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06095505)) |
| Dec 2027 to Mar 2028 | [Alisertib topline data readout](https://sec-api.dev/pdufa/alisertib) | PBYI |  | scheduled | "NCT06369285 (A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06369285)) |
| December 2027 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI |  | scheduled | "NCT06369285 (A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06369285)) |
| Mar to Jun 2028 | [Alisertib topline data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer ( SCLC ) | scheduled | "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465757)) |
| March 2028 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer ( SCLC ) | scheduled | "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465757)) |

## Drugs

- [Alisertib](https://sec-api.dev/pdufa/alisertib): with her2-negative, hr-positive metastatic breast cancer, with extensive-stage small cell lung cancer, chemotherapy-naïve her2-negative, hormone receptor-positive metastatic breast cancer, with extensive stage small cell lung cancer, with advanced small cell lung cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- [Nerlynx (neratinib maleate)](https://sec-api.dev/pdufa/neratinib): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pbyi/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PBYI catalysts: PUMA BIOTECHNOLOGY, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pbyi/catalysts

```bibtex
@misc{secapidev_companies_pbyi_catalysts_20261116,
  title        = {PBYI catalysts: PUMA BIOTECHNOLOGY, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pbyi/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pbyi_catalysts_20261116","title":"PBYI catalysts: PUMA BIOTECHNOLOGY, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pbyi/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
